Post Treatment Quality of Life among Sri Lankan Women with Breast Cancer

Ravindri Jayasinghe  
Department of Surgery, Faculty of Medicine, University of Colombo  
https://orcid.org/0000-0002-7258-2789

Ashan Fernando  
Department of Surgery, Faculty of Medicine, University of Colombo

Umesh Jayarajah  
Department of Surgery, Faculty of Medicine, University of Colombo  
umeshe.jaya@gmail.com  
https://orcid.org/0000-0002-0398-5197

Sanjeewa Seneviratne  
Department of Surgery, Faculty of Medicine, University of Colombo

Research article

Keywords: quality of life, breast cancer, mastectomy, breast-conserving surgery, Sri Lanka

Posted Date: November 17th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-108190/v1

License: ☺ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on March 23rd, 2021. See the published version at https://doi.org/10.1186/s12885-021-08055-5.
Abstract

**Background** This study was conducted to evaluate post-treatment long-term quality of life (QOL) in breast cancer patients and to determine its association with the type of surgery.

**Methods** All women with non-metastatic breast cancer who underwent surgery for breast cancer at the Professorial Surgical Unit, Colombo during 2015–2018 and completed a minimum of one year follow up after surgery were invited to participate in the study. Fifty-four women who responded were analysed using the validated EORTC QLQ-C30 and QLQ-BR23 questionnaires. Non-parametric tests were used for statistical analyses.

**Results** The mean age was 59 years (range 36–81). A majority (61%, n = 33) underwent mastectomy and the rest (n = 19, 45%) breast conservation surgery (BCS). The mean QLQ-C30 score was 68.8 (range 8.3–100) and the mean scores for physical function, role function, emotional function, cognitive function, and social function were 71.4, 81.5, 77.0, 80.2, and 86.4, respectively. The mean scores for body image, sexual functioning, sexual enjoyment, future perspective, systemic therapy, breast symptoms, arm symptoms, and hair loss assessed by the QLQ-BR23 were 76.4, 18.3, 33.3, 73.6, 30.5, 16.2, 23.4 and 32.7, respectively. No significant differences (P > 0.05) were noted in global health status, physical function, role function, emotional function, cognitive function and social function between BCS and mastectomy. QLQ-BR23 body image, sexual functioning, sexual enjoyment and future perspective also did not differ significantly (p > 0.05) between the two groups.

**Conclusions** Sexual functioning and enjoyment, breast and arm symptoms and hair loss contributed to poor QOL while the impact on global health status including physical, social and emotional functions were minimal. Type of surgery did not appear to be associated with QOL. Future studies with a larger sample sizes will be helpful to further study these factors.

**Background**

Breast cancer is the most commonly diagnosed cancer in women with over two million new patients diagnosed in 2018. Furthermore, it is the commonest cause for cancer-related death in women with over 600,000 deaths the same year [1]. In Sri Lanka, breast cancer is the commonest malignancy with a increasing incidence, especially in the post-menopausal women [2].

Advancements in diagnosis and treatment have substantially improved the survival rates from breast cancer over last two to three decades with a majority of women achieving a complete cure [3, 4]. Although these advances would add ‘years to patients’ lives’, it may not add ‘life to patients’ years’ shifting the focus towards improving the quality of life of patients [5]. This has led to post-treatment QOL being recognized as an important issue among the survivors due to the negative impacts of treatment [5, 6]. QOL in these women is affected not only due to the morbidity linked with the treatment but also due to the additional burden from psychosocial aspects such as changes in lifestyle, sexual dysfunction, and alteration of body image [5].
In the South East Asian region, the evaluation of response to therapy is largely limited to the use of traditional markers such as disease free survival and overall survival. However, worldwide, especially in the West there is an increasing focus towards optimising the health-related quality of life among survivors [7]. The concept of QOL is broad given the complexity of the aspects involved. Health-related quality of life (HRQL) broadly involves the patients’ outlook on the impact of illness, impairments, and the impact of therapeutic interventions in the context of quality of life [8]. There are a range of generic and specific instruments developed to assess the quality of life (QOL). As generic instruments are not specific to a particular health condition, specific instruments are made with improved sensitivity to detect changes after an intervention. Amongst the specific instruments available, the instrument developed by the European organization for Research and Treatment of Cancer (EORTC) to evaluate the health-related quality of life by a core questionnaire QLQ-C30 stands out being widely used in literature with proven reliability and reproducibility [9, 10]. The validity of this tool in evaluating health-related quality of life among Sri Lankan women with breast cancer had been proven previously [11].

Two main modes of surgical treatment of breast cancer include breast conservation surgery (BCS) and mastectomy. Evidence has proven BCS followed by whole breast irradiation and total mastectomy to carry nearly equal oncological outcomes in early breast cancer [12]. However, the choice on type of surgery would depend on several patient and disease related factors. Furthermore, patients may opt for mastectomy due to several reasons such as fear of recurrence, aversion to radiotherapy and the surgeons’ expertise. Breast cancer surgery in most patients would contribute to some degree of both short and longer-term morbidity which may vary depending on patient and tumour factors. A systematic review in 2016 established the negative implications of surgical complications on patient psychosocial outcomes and the QOL [13].

Several studies over the years have focused on QOL after surgery for breast cancer. Although most have shown BCS to be superior to mastectomy, some had shown no significant difference in QOL [14–17]. Several long term follow-up studies have shown no improvement in body image, sexual function over time after BCS versus mastectomy [14, 18]. Most literature evaluating post-surgical QOL in patients with breast cancer are from the Western world which might significantly differ from the South Asian region due to the sociocultural differences. Even amongst Sri Lankan women, differences are likely to exist depending on the different social, ethnic, and educational groups. Therefore, there is a gap in knowledge in the local context regarding many aspects of QOL after treatment of breast cancer. This study was conducted with the aim of evaluating the post-treatment long-term quality of life (QOL) in breast cancer patients and to determine its association with the type of surgery.

**Methods**

All women with non-metastatic breast cancer who underwent surgery for breast cancer at the Professorial Surgical Unit, Colombo during 2015–2018 and completed a minimum of one year follow up after surgery having an ECOG score of 0–2 were invited via phone calls and mail to participate in the study. Fifty-four
women who responded were analysed using the validated EORTC QLQ-C30 and QLQ-BR23 questionnaires[19, 20]. Non-parametric tests were used for statistical analyses.

Women with a previous history of breast or other types of cancer were excluded. Ethical approval for this study was obtained from the Ethical Review Committee, Faculty of Medicine Colombo (EC: 17–126).

The QLQ-C30 questionnaire includes 30 items to assess five functional scales (physical, cognitive, role, emotional, and social), three symptom scales (Fatigue, pain, nausea and vomiting) and a global health and quality of life scale [9]. QLQ-BR23 includes 23 items including four functional scales and four symptom scales where a higher score in functional scales would represent better functioning and a higher score in symptom scales would indicate increased symptom related issues. Additional data were obtained with regard to the type of surgery - BCS or mastectomy and the menopausal status.

**Statistical analysis**

The data were coded and analysed according to the scoring protocol described in the EORTC QLQ-30 manual by Fayers et al using SPSS version 24 [9, 21]. Non-parametric tests including Chi square ($\chi^2$) test, Mann-Whitney U test and Spearman correlation test were used for univariate statistical analyses. QOL scores were compared between women undergoing BCS versus mastectomy. A p value < 0.05 was considered as statistically significant.

**Results**

Fifty-four female patients were included in the study with a mean age of 59.0 years (range 36–81) with 61.1% (n = 33) being less than 60 years. Majority of the women were postmenopausal (85.2%, n = 46). A majority (61.1%, n = 33) underwent mastectomy as the primary surgery and the rest (45%, n = 19) underwent BCS. Axillary node dissection was performed in 59.2% (n = 32) and the rest only a sentinel lymph node biopsy (Table 1).

**Table 01: Socio-demographic characteristics and study sample variables**
| Variables                  | Frequency | Percentage |
|----------------------------|-----------|------------|
| **Age**                    |           |            |
| £60 yrs                    | 33        | 61.11%     |
| >60 yrs                    | 21        | 38.9%      |
| **Marital status**         |           |            |
| Married                    | 51        | 94.4%      |
| Unmarried                  | 3         | 5.6%       |
| **Educational level**      |           |            |
| Primary                    | 4         | 7.4%       |
| Secondary                  | 43        | 79.6%      |
| Graduate                   | 2         | 3.7%       |
| Postgraduate               | 3         | 5.6%       |
| **Occupation**             |           |            |
| Actively employed          | 10        | 18.5%      |
| Retired/homemaker          | 5         | 9.3%       |
| **Menopausal status**      |           |            |
| Premenopausal              | 7         | 13.0%      |
| Postmenopausal             | 46        | 85.2%      |
| **Type of surgery**        |           |            |
| BCS§                       | 19        | 35.2%      |
| Mastectomy                 | 33        | 61.1%      |
| **Axillary surgery**       |           |            |
| Sentinel lymph node biopsy | 16        | 29.6%      |
| Axillary lymph node dissection | 32    | 59.3%      |
| **Adjuvant chemotherapy**  |           |            |
| Yes                        | 23        | 42.6%      |
| No                         | 9         | 16.7%      |
| No information             | 22        | 40.7%      |
| **Adjuvant radiotherapy**  |           |            |
Breast conservation surgery;

The mean EORTC QLQ-C30 score was 68.8 (range: 8.3–100) and the mean scores for physical function, role function, emotional function, cognitive function, and social function were 71.4 (range: 33.3–100), 81.5 (range: 0-100), 77 (range: 0-100), 80.2 (range: 33.3–100), 86.4 (range: 0-100), respectively. The EORTC QLQ-C30 scores in the less than 60-year age group (n = 33) was not any different than the older patients (greater than or equal to 60 years) (Table 2).

Table 02: Association between socio-demographic characteristics and Global health status
| Variables                  | Age   | Type of surgery | Axillary surgery |
|---------------------------|-------|-----------------|------------------|
|                           | ≤60 years | >60 years | BCS | Mastectomy +/- reconstruction | Sentinel lymph node biopsy | Axillary lymph node dissection |
| EORTC QLQ-C30* score      |       |                |     |                              |                             |                              |
| **Global health status**  | Median | 83.3          | 58.3| 83.3                          | 66.7                        | 70.8                          | 75                   |
|                           | Range  | 8.3-100       | 25-100| 25-100                      | 8.33-100                    | 8.33-100                      | 25-100               |
|                           | p      | 0.135          | 0.414|                             |                             |                             | 0.550                |
| **Physical function**     | Median | 73.33         | 73.33| 73.33                        | 73.33                       | 66.67                         | 80                   |
|                           | Range  | 33.3-100      | 41.7-100| 33.3-100                   | 33.3-100                    | 33.3-100                      | 33.3-100             |
|                           | p      | 0.531          | 0.962|                             |                             |                             | 0.181                |
| **Role function**         | Median | 83.3          | 83.3 | 83.3                        | 83.3                       | 91.7                          | 83.3                 |
|                           | Range  | 0-100         | 16.7-100| 16.7-100                  | 0-100                       | 66.7-100                      | 16.7-100             |
|                           | p      | 0.087          | 0.429|                             |                             |                             | 0.78                 |
| **Emotional function**    | Median | 91.7          | 75   | 91.7                        | 75                          | 91.7                          | 91.7                 |
|                           | Range  | 0-100         | 16.7-100| 0-100                      | 0-100                       | 16.7-100                      | 16.7-100             |
|                           | p      | 0.587          | 0.745|                             |                             |                             | 0.759                |
| **Cognitive function**    | Median | 83.3          | 83.3 | 83.3                        | 83.3                       | 83.3                          | 83.3                 |
|                           | Range  | 33.3-100      | 50-100| 50-100                      | 33.3-100                    | 33.3-100                      | 50-100               |
|                           | p      | 0.108          | 0.309|                             |                             |                             | 0.501                |
| **Social function**       | Median | 100           | 100  | 100                         | 100                         | 100                           | 100                  |
|                           | Range  | 16.7-100      | 0-100 | 0-100                       | 16.7-100                    | 50-100                        | 0-100                |
|                                  | Median | 86.11 | 83.33 | 100 | 83.33 | 95.83 | 83.33 |
|----------------------------------|--------|-------|-------|-----|-------|-------|-------|
| **BR 23 Score**                  |        |       |       |     |       |       |       |
| **Body image**                   |        |       |       |     |       |       |       |
| **Median**                       |        | 16.7  | 16.7  | 100 | 41.7  | 16.7  | 16.7  |
| **Range**                        |        | 16.7-100 | 16.7-100 | 16.7-100 | 16.7-100 | 16.7-100 | 16.7-100 |
| **p**                            |        | 0.874 | 0.375 | 0.645 | 0.874 | 0.375 | 0.645 |
| **Sexual functioning**           |        |       |       |     |       |       |       |
| **Median**                       |        | 16.7  | 0     | 16.7 | 8.3   | 16.7  | 0     |
| **Range**                        |        | 0-100 | 0-100 | 0-100 | 0-100 | 0-100 | 0-100 |
| **p**                            |        | 0.145 | 0.172 | 0.236 | 0.145 | 0.172 | 0.236 |
| **Sexual enjoyment**             |        |       |       |     |       |       |       |
| **Median**                       |        | 33.3  | 16.7  | 33.3 | 33.3  | 33.3  | 33.3  |
| **Range**                        |        | 0-100 | 0-66.7| 0-100 | 0-100 | 0-100 | 0-100 |
| **p**                            |        | 0.57  | 0.283 | 0.393 | 0.57  | 0.283 | 0.393 |
| **Future perspective**           |        |       |       |     |       |       |       |
| **Median**                       |        | 100   | 66.7  | 100 | 100   | 83.3  | 100   |
| **Range**                        |        | 0-100 | 0-100 | 0-100 | 0-100 | 0-100 | 0-100 |
| **p**                            |        | 0.227 | 0.949 | 0.595 | 0.227 | 0.949 | 0.595 |
| **Systemic therapy**             |        |       |       |     |       |       |       |
| **Median**                       |        | 23.8  | 28.5  | 28.5 | 23.8  | 35.7  | 19.1  |
| **Range**                        |        | 0-90.4 | 0-90.4 | 0-90.4 | 0-90.4 | 9.5-90.4 | 0-90.5 |
| **p**                            |        | 0.636 | 0.811 | 0.009 | 0.636 | 0.811 | 0.009 |
| **Breast symptoms**              |        |       |       |     |       |       |       |
| **Median**                       |        | 16.7  | 16.7  | 16.7 | 16.7  | 16.7  | 16.7  |
| **Range**                        |        | 0-66.7 | 0-66.7 | 0-66.7 | 0-33.3 | 0-66.7 | 0-66.7 |
|                | Median | Range | p    | Median | Range | p    | Median | Range | p    |
|----------------|--------|-------|------|--------|-------|------|--------|-------|------|
| **Arm symptoms** | 22.2   | 0-77.8| 0.27 | 11.1   | 0-55.6| 0.469| 22.2   | 0-77.8| 0.393|
| **Hair loss**   | 0      | 0-100 | 0.689| 33.3   | 0-100 | 0.185| 0      | 0-100 | 0.84 |
| **Arm symptoms** | 22.2   | 0-66.7| 0.689| 22.2   | 0-66.7| 0.185| 22.2   | 0-66.7| 0.84 |
| **Hair loss**   | 0      | 0-100 | 0.084| 16.7   | 0-100 | 0.859| 0      | 0-100 | 0.009|
| **Arm symptoms** | 11.1   | 0-77.8| 0.084| 22.2   | 0-77.8| 0.859| 22.2   | 0-77.8| 0.009|
| **Hair loss**   | 33.3   | 0-100 | 0.689| 0      | 0-100 | 0.009| 33.3   | 0-100 | 0.859|
| **Arm symptoms** | 22.2   | 0-66.7| 0.689| 22.2   | 0-66.7| 0.185| 22.2   | 0-66.7| 0.84 |
| **Hair loss**   | 0      | 0-100 | 0.084| 16.7   | 0-100 | 0.859| 0      | 0-100 | 0.009|
| **Arm symptoms** | 11.1   | 0-77.8| 0.084| 22.2   | 0-77.8| 0.859| 22.2   | 0-77.8| 0.009|
| **Hair loss**   | 33.3   | 0-100 | 0.689| 0      | 0-100 | 0.009| 33.3   | 0-100 | 0.859|

* European organization for Research and Treatment of Cancer Quality of Life Questionnaire C30

** European organization for Research and Treatment of Cancer Quality of Life Questionnaire BR 23

The mean scores for body image, sexual functioning, sexual enjoyment, future perspective, systemic therapy, breast symptoms, arm symptoms, and hair loss assessed by the QLQ BR-23 were 76.4 (range: 16.67–100), 18.3 (range: 0-100), 33.3 (range: 0-100), 73.6 (range: 0-100), 30.5 (range: 0-90.5), 16.2 (range: 0-66.7), 23.45 (range: 0-77.8), 32.7 (range: 0-100), respectively.

Significant negative correlation was noted between the overall EORTC QLQ-C30 score and the decreasing age (p = 0.022). No significant difference was noted in the global health status (p = 0.41), physical function (p = 0.96), role function (p = 0.42), emotional function (p = 0.74), cognitive function (p = 0.30), and social function (p = 0.19) parameters in the two groups who underwent BCS versus mastectomy as reported by the EORTC QLQ-C30. The parameters assessed by the QLQ BR-23 such as body image (p = 0.37), sexual functioning (p = 0.17), sexual enjoyment (p = 0.28), future perspective (p = 0.94), systemic therapy (p = 0.81), breast symptoms (p = 0.46), arm symptoms (p = 0.18), and hair loss (p = 0.859) were also similar in the two groups who underwent BCS compared with mastectomy (Table 2).

**Discussion**

This prospective cohort study evaluated the post-treatment long-term QOL in Sri Lankan female patients diagnosed with breast cancer using the validated EORTC QLQ-C30 and BR-23 tools have shown
substantially poor QOL in sexual functioning and enjoyment, breast and arm symptoms and hair loss domains while the impact on global health status including physical, social and emotional functions were minimal. The mean EORTC QLQ-C30 score of 68.8 indicated that our patients health related quality of life (HRQL) is comparable with average global figures (mean 61.8+/−24.6) as well as previously published local figures (mean 50+/−24.3) [11, 22]. However, our study did not demonstrate an association with the type of surgery and the post-treatment long-term QOL of patients according to EORTC QLQ-C30 and QLQ-BR23 scores (P > 0.05). In addition, a negative correlation was observed with the overall EORTC QLQ-C30 score and the age (p = 0.022) where younger patients showed a significantly better QOL scores.

A majority of previous studies investigating QOL with type of breast surgery from Western countries have shown conflicting results although most studies have shown BCS to be superior to mastectomy [14–17, 23, 24]. A study by Chow et al on symptom burden and QOL in breast cancer patients treated with BCS versus mastectomy showed mastectomy patients to have a significantly lower QOL, lower physical and emotional wellbeing, higher pain, anxiety, drowsiness and loss of appetite compared with BCS [23]. However, in that study, the QOL was assessed using a different tool compared to the present study [23]. A study done in Germany by Engel et al using similar assessment tools concluded that the patients undergoing BCS had better scores in most variables and had a significantly better overall QOL. In this study, mastectomy patients had lower body image, limited role function, less sexual activity, increased insecurity and had their day today activities affected to a greater extent [18].

Few long-term follow-up studies have shown no differences in body image, sexual function over time among patients who underwent BCS in comparison with mastectomy [14, 24]. A large prospective cohort study by Ganz et al comparing patients undergoing BCS versus mastectomy found no significant differences in quality of life, psychosocial adjustment, rehabilitation needs, or mood [14]. Another large prospective cohort study by Browne et al that analysed the association between complications and QOL after breast reconstruction and mastectomy showed that surgical complications had little or no association with the quality of life among patients who underwent mastectomy with or without reconstruction [24]. Furthermore, surgical complications did not have a significant impact on the their physical wellbeing scores [24]. The reasons behind the unexpected lack of improvement in quality of life after BCS may be explained by the fear of recurrence or the effects of post-operative radiotherapy. This could be further influenced by local sociocultural and educational factors as well as personal beliefs. Furthermore, absence of a deterioration of body image in our sample may also suggest the absence of a difference in QOL parameters in relation to type of surgery.

In comparison with the global values for QLQ-30 in women after breast cancer treatment, the role function, emotional function, and social function showed substantially better QOL values. However, compared to global parameters, the scores of BR-23 such as body image, sexual functioning and sexual enjoyment appear to be lower [22]. The reasons for these differences could be due to the sociocultural disparities in the local population compared to the women from the Western countries. Most evidence on QOL after breast cancer surgery are from the Western world where the ‘value’ of an intact breast may vary from Sri Lankan women due to differences in socio-cultural values and body image. Higher mean age of
the study population (59 years) with a majority of the women being postmenopausal (85.2%) might also have contributed to the observed lack of difference between mastectomy and BCS.

According to our findings, the low sores in breast related symptoms measured by BR-23 seems to be a major contributing factor for the lower QOL in breast cancer patients. Taking this into consideration, it is necessary to take measures to address the burden of breast related symptoms of these patients following surgery as these are easily preventable with adequate care. The HRQL of these patients may be improved by simple measures such as addressing sexual issues by referring them for counselling and prescribing topical applications, offering physiotherapy to alleviate arm symptoms, provision of wigs to combat hair loss following treatment. Furthermore, in the Sri Lankan context patients would be reluctant to bring out these sensitive issues themselves with the doctors. Provision of regular contact with the patients through trained cancer care nurses to recognize these issues and provide advice may help improve QOL in these domains which ultimately will help improve overall QOL.

Our study was the first of its kind performed in the Sri Lankan context. The main limitations of this study is the smaller sample size, the inequality of age distribution and the absence of a control group. Several other contributors for morbidity following surgery for breast cancer such as sensory complaints of the ipsilateral arm, duration of disease, and a comparison before and after surgery was not considered in the present study which seem necessary in evaluating the QOL. Further prospective studies with larger sample sizes are deemed essential in the local context incorporating these other factors that may affect QOL among breast cancer patients.

**Conclusions**

Sexual functioning and enjoyment, breast and arm symptoms and hair loss contributed to poor QOL in women after treatment for breast cancer while the impact on global health status including physical, social and emotional functions were minimal. Type of surgery did not appear to be associated with QOL. Age was the only statistically significant factor associated with QOL, where younger patients showed a significantly better QOL. Measures should be implemented to help women with breast related symptoms especially sexual, arm and hair loss related symptoms which contribute significantly to poor QOL following surgery. Further studies with larger sample sizes will be helpful to confirm these findings and to identify strategies to improve QOL in these specific domains.

**List Of Abbreviations**

QOL: Quality of life

BCS: Breast conservation surgery

HRQL: Health related quality of life

EORTC: European organization for Research and Treatment of Cancer
Declarations

Funding – None

Competing interests – All authors declare that there are no competing interests

Availability of data and materials- The data used in the above analysis will be available on reasonable request from the corresponding author.

Code availability- Not applicable

Author’s Contributions- RJ, AF and UJ contributed to concept and design of study, acquisition of data, analysis, interpretation of data, drafting the article and final approval of the version to be published. SS contributed to concept and design of study, revising it critically for important intellectual content; and final approval of the version to be published. All authors have read and approved the manuscript

Ethics approval and consent to participate- Ethics approval was obtained from the Ethics Review Committee of the Faculty of Medicine, University of Colombo, Sri Lanka (EC-17-126). All patients gave informed written consent before participating in this study.

Consent for publication- Not obtained

Acknowledgements- None

References

1. Cancer Today - GLOBOCAN [https://gco.iarc.fr/today/home]
2. Fernando A, Jayarajah U, Prabashani S, Fernando EA, Seneviratne SA: Incidence trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer database. BMC cancer 2018, 18(1):482.
3. Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS: Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. bmj 2012, 344:e2718.
4. Basnayake O, Jayarajah U, Seneviratne S: Management of axilla in breast cancer: the past, present and the future. Sri Lanka Journal of Surgery 2018, 36(4).
5. Bertan FdC, Castro EKd: Qualidade de vida e câncer: revisão sistemática de artigos brasileiros. Psico (Porto Alegre) 2009:366-372.
6. Nounou MI, EIAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H: Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer: Basic and Clinical Research 2015, 9s2:BCBCR.S29420.
7. Aaronson N: Quality of Life and clinical trials. Lancet 1995, 346(8966):1-2.
8. Barbosa PA, Cesca RG, Pacífico TED, Leite ICG: Quality of life in women with breast cancer, after surgical intervention, in a city in the zona da mata region in Minas Gerais, Brazil. Revista Brasileira de Saúde Materno Infantil 2017, 17(2):385-399.

9. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtnner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI: Journal of the National Cancer Institute 1993, 85(5):365-376.

10. Fas M, Mrdo I, Ms M: Validity, reliability and understanding of the eortc-c30 and eortcBr23, quality of life questionnaires specific for breast cancer. rev Bras epidemiol 2013, 16(2):352-363.

11. Jayasekara H, Rajapaksa LC, Aaronson NK: Quality of life in cancer patients in South Asia: psychometric properties of the Sinhala version of the EORTC QLQ-C30 in cancer patients with heterogeneous diagnoses. Quality of Life Research 2008, 17(5):783-791.

12. National Institutes of Health: Treatment of early stage breast cancer. In: NIH Consensus Development Conference: 1997; 1991.

13. Pinto A, Faiz O, Davis R, Almoudaris A, Vincent C: Surgical complications and their impact on patients’ psychosocial well-being: a systematic review and meta-analysis. BMJ open 2016, 6(2).

14. Ganz PA, Anne Schag CC, Lee JJ, Polinsky ML, Tan SJ: Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery? Cancer 1992, 69(7):1729-1738.

15. Kiebert G, De Haes J, Van de Velde C: The impact of breast-conserving treatment and mastectomy on the quality of life of early-stage breast cancer patients: a review. Journal of Clinical Oncology 1991, 9(6):1059-1070.

16. Rietman JS, Dijkstra PU, Hoekstra HJ, Eisma WH, Szabo BG, Groothoff JW, Geertzen JH: Late morbidity after treatment of breast cancer in relation to daily activities and quality of life: a systematic review. European Journal of Surgical Oncology (EJSO) 2003, 29(3):229-238.

17. Freitas-Silva R, Conde DM, Freitas-Júnior Rd, Martinez EZ: Comparison of quality of life, satisfaction with surgery and shoulder-arm morbidity in breast cancer survivors submitted to breast-conserving therapy or mastectomy followed by immediate breast reconstruction. Clinics 2010, 65(8):781-787.

18. Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Hölzel D: Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study. The breast journal 2004, 10(3):223-231.

19. EORTC QLQ-C30 (version 3) [https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf]

20. EORTC QLQ-BR23 [https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-BR23-English-1.1.pdf]

21. Fayers P, Aaronson NK, Bjordal K, Sullivan M: EORTC QLQ-C30 scoring manual: European Organisation for Research and Treatment of Cancer; 1995.
22. Scott NW, Fayers P, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Gundy C, Koller M, Petersen MA, Sprangers MA: *EORTC QLQ-C30 reference values manual*. 2008.

23. Chow R, Pulenzas N, Zhang L, Ecclestone C, Leahey A, Hamer J, DeAngelis C, Bedard G, McDonald R, Bhatia A: *Quality of life and symptom burden in patients with breast cancer treated with mastectomy and lumpectomy*. *Supportive Care in Cancer* 2016, **24**(5):2191-2199.

24. Browne JP, Jeevan R, Gulliver-Clarke C, Pereira J, Caddy CM, van der Meulen JH: *The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer*. *Cancer* 2017, **123**(18):3460-3467.